The US FDA has accepted a novel leukemia treatment which is first gene therapy it has passed to hit the market in the US. Kymriah is the name by which treatment is known focuses to provide a second chance to some patients after the first line drugs have not succeeded.
This therapy known as chimeric antigen receptor T-cell therapy or CAR-T involves taking a patient’s own immune cell that is genetically modified in the lab using a virus. This provides the cell with a capability to identify and kill the source of cancer.
FDA Commissioner Dr. Scott Gottlieb said in a statement that we are entering a new era in medical revolution with the capability to reprogram patient’s own cell to assault a deadly cancer. Dr. Stephan Grupp, director of cancer immunotherapy at Children’s Hospital of Philadelphia, said that we are witnessing such phenomena for the first time and this therapy may set a new standard of care for patients suffering from this disease.
An FDA advisory committee had advocated the theory for acceptance in July to cure the relapse of blood cancer known as B-cell acute lymphoblastic leukemia, or ALL. The recently researched data shows that patients who are undergoing this treatment have 89% chance of surviving for at least six months whereas 79% chances of survival for at least one year.
According to the US Centers for Disease Control and Prevention almost 5000 people were determined with ALL in 2014. Majority of them were children and teens. This is said to be the most usual type of cancer in children according to National Cancer Institute.